Zhifang Wu

Prof. Zhifang Wu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2023 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
JAJie An
Jie An
XHXinyi He
Xinyi He
HMHuizhu Ma
Huizhu Ma
YLYanglei Li
Yanglei Li
YLYayuan Li
Yayuan Li
SLSijin Li
Sijin Li

7 December 2020 in IEEE Transactions on Biomedical Engineering
Verified
Journal Article
Closed access
NXNuobei Xie
Nuobei Xie
KGKuang Gong
Kuang Gong
NGNing Guo
Ning Guo
ZQZhixing Qin
Zhixing Qin
ZWZhifang Wu
Zhifang Wu
Quanzheng LiQuanzheng Li
Quanzheng Li
Positron emission tomography (PET) is widely used for clinical diagnosis. As PET suffers from low resolution and high noise, numerous efforts try to incorporate anatomical priors into PET image reconstruction, especially with the development of hybrid PET/CT and PET/MRI systems. In this work, we proposed a cube-based 3D structural convolutional sparse coding (CSC) concept for penalized-likelihood PET image reconstruction, named 3D PET-CSC. The proposed 3D PET-CSC takes advantage of the convolutional operation and manages to incorporate anatomical priors without the need of registration or supervised training. As 3D PET-CSC codes the whole 3D PET image, instead of patches, it alleviates the staircase artifacts commonly presented in traditional patch-based sparse coding methods. Compared with traditional coding methods in Fourier domain, the proposed method extends the 3D CSC to a straightforward approach based on the pursuit of localized cubes. Moreover, we developed the residual-image and order-subset mechanisms to further reduce the computational cost and accelerate the convergence for the proposed 3D PET-CSC method. Experiments based on computer simulations and clinical datasets demonstrate the superiority of 3D PET-CSC compared with other reference methods.

1 February 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
NMNing Ma
Ning Ma
WYWeihua Yang
Weihua Yang
QWQiannan Wang
Qiannan Wang
CCCaozhe Cui
Caozhe Cui
YHYiyi Hu
Yiyi Hu
ZWZhifang Wu
Zhifang Wu
Objective: This study aimed to evaluate the value of 18F-FDG PET/CT radiomics in predicting EGFR gene mutations in non-small cell lung cancer by meta-analysis.Methods: The PubMed, Embase, Cochrane Library, Web of Science, and CNKI databases were searched from the earliest available date to June 30, 2023. The meta-analysis was performed using the Stata 15.0 software. The methodological quality and risk of bias of included studies were assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 and Radiomics Quality Score criteria. The possible causes of heterogeneity were analyzed by meta-regression.Results: A total of 17 studies involving 3763 non-small cell lung cancer patients were finally included. We analyzed 17 training cohorts and 10 validation cohorts independently. Within the training cohort, the application of 18F-FDG PET/CT radiomics in predicting EGFR mutations in NSCLC demonstrated a sensitivity of 0.76 (95% CI: 0.70-0.81) and a specificity of 0.78 (95% CI: 0.74-0.82), accompanied by a positive likelihood ratio of 3.5 (95% CI:3.0-4.2), a negative likelihood ratio of 0.31 (95% CI: 0.24-0.39), a diagnostic odds ratio of 11.0 (95% CI: 8.0-16.0), and an area under the curve (AUC) of 0.84 (95% CI: 0.80-0.87). In the validation cohort, the values included a sensitivity of 0.76 (95% CI: 0.67-0.83), a specificity of 0.75 (95% CI: 0.68-0.80), a positive likelihood ratio of 3.0 (95% CI:2.4-3.8), a negative likelihood ratio of 0.32 (95% CI: 0.24-0.44), a diagnostic odds ratio of 9 (95% CI: 6-15), and an AUC of 0.82 (95% CI: 0.78-0.85). The average Radiomics Quality Score (RQS) across studies was 10.47 ± 4.72. Meta-regression analysis identifies the application of deep learning and regions as sources of heterogeneity.Conclusion: 18F-FDG PET/CT radiomics may be useful in predicting mutation status of the EGFR gene in non-small cell lung cancer.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO, identifier CRD42022385364.

28 March 2025 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
MLMin Li
Min Li
KCKaile Chu
Kaile Chu
QZQin Zhou
Qin Zhou
HWHongliang Wang
Hongliang Wang
WZWenjun Zhang
Wenjun Zhang
SLSijin Li
Sijin Li

1 November 2021 in European Journal of Radiology
Verified
Journal Article
Closed access
DLDandan Li
Dandan Li
YCYanfen Cui
Yanfen Cui
LHLina Hou
Lina Hou
ZBZeyu Bian
Zeyu Bian
ZYZhao Yang
Zhao Yang
XYXiaotang Yang
Xiaotang Yang

1 January 2023 in Nanotheranostics
Verified
Journal Article
Open access
PDF file
CZChunfang Zan
Chunfang Zan
JAJie An
Jie An
ZWZhifang Wu
Zhifang Wu
SLSijin Li
Sijin Li
Atherosclerosis, an inflammation-driven chronic blood vessel disease, is a major contributor to devastating cardiovascular events, bringing serious social and economic burdens. Currently, non-invasive diagnostic and therapeutic techniques in combination with novel nanosized materials as well as established molecular targets are under active investigation to develop integrated molecular imaging approaches, precisely visualizing and/or even effectively reversing early-stage plaques. Besides, mechanistic investigation in the past decades provides many potent candidates extensively involved in the initiation and progression of atherosclerosis. Recent hotly-studied imaging nanoprobes for detecting early plaques mainly including optical nanoprobes, photoacoustic nanoprobes, magnetic resonance nanoprobes, positron emission tomography nanoprobes, and other dual- and multi-modality imaging nanoprobes, have been proven to be surface functionalized with important molecular targets, which occupy tailored physical and biological properties for atherogenesis. Of note, these engineering nanoprobes provide long blood-pool residence and specific molecular targeting, which allows efficient recognition of early-stage atherosclerotic plaques and thereby function as a novel type of precise diagnostic tools as well as potential therapeutic carriers of anti-atherosclerosis drugs. There have been no available nanoprobes applied in the clinics so far, although many newly emerged nanoprobes, as exemplified by aggregation-induced emission nanoprobes and TiO2 nanoprobes, have been tested for cell lines in vitro and atherogenic animal models in vivo, achieving good experimental effects. Therefore, there is an urgent call to translate these preclinical results for nanoprobes into clinical trials. For this reason, this review aims to give an overview of currently investigated nanoprobes in the context of atherosclerosis, summarize relevant published studies showing applications of different kinds of formulated nanoprobes in early detection and reverse of plaques, discuss recent advances and some limitations thereof, and provide some insights into the development of the new generation of more precise and efficient molecular nanoprobes, with a critical property of specifically targeting early atherosclerosis.